Track topics on Twitter Track topics that are important to you
The Swiss medtech company Symetis has launched a €55M IPO to accelerate the development of its next-generation heart valve replacement solutions. Symetis develops next-generation heart valve replacements for the treatment of cardiac valve conditions. With its current €55M IPO on Euronext ...
This awesome article MedTech Company Launches Large €55M IPO for Artificial Heart Valves appeared first on Labiotech.eu. Be kind and don't copy it without asking ;)
Original Article: MedTech Company Launches Large €55M IPO for Artificial Heart ValvesNEXT ARTICLE
Cardiology is a specialty of internal medicine. Cardiac electrophysiology : Study of the electrical properties and conduction diseases of the heart. Echocardiography : The use of ultrasound to study the mechanical function/physics of the h...
Cardiovascular disease (CVD)
Acute Coronary Syndromes (ACS) Blood Cardiovascular Dialysis Hypertension Stent Stroke Vascular Cardiovascular disease (CVD) includes all the diseases of the heart and circulation including coronary heart disease (angina...